REFERENCES
- SEER Cancer Statistics Review, L. A. G. Ries, D. Melbert, M. Krapcho, D. G. Stinchcomb, N. Howlader, M. J. Horner, et al. National Cancer Institute, Bethesda, MD 1975–2005, http://seer.cancer.gov/csr/1975_2005 based on November 2007 SEER data submission, posted to the SEER web site, 2008
- Dawood S., Broglio K., Hortobagyi G., Giordano S. Trends in survival of stage iv breast cancer (bc) among Caucasian and African American (AA) bc patients (pts). J Clin Oncol 2007, ASCO Annual Meeting Proceedings, 25 (Abstract 1000)
- American Cancer Society. Breast Cancer Facts & Figures 2007–2008. American Cancer Society, Inc, Atlanta, GA 2007–2008
- Lu C., Lin Y., Chang H. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital. Chang Gung Med J 2007; 30: 33–40
- Grothey A., Sugrue M., Hedrick E., Purdie D., Yi J. D., Kozloff M. Investigators tBS: association between exposure to bevacizumab (bv) beyond first progression (bbp) and overall surivival (os) in patients with metastatic colorectal cancer (mcrc): results from a large observational study (BRITE). J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part 1 (June 20, Supplement) 25, Abstract 4036
- Tripathy D. S., Slamon D. J., Cobleigh M., Arnold A., Salah M., Mortimer J. E., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063–1070
- Goetz M., Knox S., Suman V., Rae J., Safgren S., Ames M., et al. The impact of cytochrome p450 2d6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113–121
- Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817–2826
- Del Bianco S., Rondinelli R. Trastuzumab-containing therapies: activity beyond disease progression in MBC—a pivotal experience. J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part I 24(18S) (June 20 Supplement) 10788
- Garcia-Saenz J., Martin M., Bueno C., Sampedro T., Lopez-Tarruella S., et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part I 24(18S) (June 20 Supplement), Abstract 10617
- Sorlie T., Perou C., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001; 98: 10869–10874
- Carey L. A., Rugo H. S., Marcom P. K., Irvin W., Ferraro M., Burrows E., et al. Tbcrc 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings 2008; 26, Abstract 1009
- Zhang B., Wright A. A., Nilsson M. E., Huskamp H. A., Maciejewski M. L., Earle C. C., et al. Associations between advanced cancer patients' end-of-life conversations and cost experiences in the final week of life. J Clin Oncol 2008, ASCO Annual Meeting Proceedings 26, 9530
- Peppercorn J., Blood E., Winer E., Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 2007; 109: 1239–1246